Asia Pacific Biosimilar Insulin Glargine & Lispro Market, By End User (Type 1 Diabetes and Type 2 Diabetes), By Country (Japan, China, India, South Korea, Bangladesh, Pakistan), Competition, Forecast & Opportunities, 2024

Biosimilar is a biological product which is similar to the reference product, already approved by authorities and marketed by companies other than the patent holder company. Insulin is a hormone produced by pancreatic cell which is responsible for absorption of glucose from the blood. Lack of insulin in the body causes diabetes. Insulin is available in different forms depending upon the sources such as animal derived, chemically synthesized or produced through recombinant technology. Insulin can be categorized as fast acting, immediate acting and long acting depending upon the absorption of insulin from the blood in the body. Glargine and lispro are two types of insulin.

The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is forecast to reach $ 786 million by 2024. Increasing expenditure on healthcare, changing eating habits and growing adoption of sedentary lifestyle are increasing the prevalence of obesity and diabetes, which in turn is driving the sales of biosimilar insulin. Additionally, increasing dependence on packaged food is further fueling growth of the market.

The Asia-Pacific Biosimilar Insulin Glargine & Lispro Market is segmented based on end-user, country and company. Based on end-user, the market can be bifurcated into Type 1 Diabetes and Type 2 Diabetes, of which the former segment dominates the market since it is an autoimmune disorder and the body does not produce any insulin.

The major players operating in the biosimilar insulin glargine & lispro market are Sanofi S.A., Eli Lilly and Company, Biocon Limited, Novo Nordisk A/S, Wockhardt, Cipla Limited, Merck Limited, and others. Major companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:
Historical Years: 2014-2017
Base Year: 2018
Estimated Year: 2019
Forecast Period: 2020–2024

Objective of the Study:

• To analyze and forecast the market size of the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
• To classify and forecast the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market based on end-user, company and country distribution.
• To identify drivers and challenges for the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
• To conduct pricing analysis for the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.
• To identify and analyze the profile of leading players operating in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.

Both primary as well as exhaustive secondary research were performed for this study. Initially, a list of manufacturers across the region was sourced. Subsequently, primary research surveys were conducted with the identified companies were conducted. While interviewing, the respondents were also enquired about their competitors. Through this technique, the manufacturers which could not be identified due to the limitations of secondary research could be included could be included. The manufacturers, distribution channels and presence of all major players across the region were analysed.

The market size of the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market was calculated by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years.

These values were sourced from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

• Biosimilar insulin glargine & lispro manufacturers, suppliers, distributors and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to insulin glargine & lispro
• Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:

In this report, the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Market, by End-User:

• Type 1 Diabetes
• Type 2 Diabetes

Market, by Country:

• Japan
• China
• India
• South Korea
• Bangladesh
• Pakistan

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Asia-Pacific Biosimilar Insulin Glargine & Lispro Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.